Journal of Peking University(Health Sciences) ›› 2018, Vol. 50 ›› Issue (6): 1108-1111. doi: 10.19723/j.issn.1671-167X.2018.06.030

• Article • Previous Articles     Next Articles

Systemic lupus erythematosus with acquired hemophilia A: a case report

Fan YANG,Yun-shan ZHOU,Yuan JIA()   

  1. Department of Rheumatology and Immunology,Peking University People’s Hospital, Beijing 100044, China
  • Received:2018-06-03 Online:2018-12-18 Published:2018-12-18
  • Contact: Yuan JIA E-mail:jiayuan1023@sina.com

RICH HTML

  

Abstract:

Acquired hemophilia A (AHA) is anunusual disease resulting from autoantibodies (inhibitors) against coagulation factor Ⅷ (FⅧ) and clinically manifests as bleeding, which sometimes can cause potentially limb-threatening or life-threatening situations. AHA is associated with cancers, auto-immune disorders, infections, dermatologic conditions and certain medications, among which it is commonly secondary to multiple rheumatologic conditions,such as rheumatoid arthritis, systemic lupus erythematosus (SLE), pollymyositis, autoimmune hemolytic anemia and undifferentiated connective tissue disease. In autoimmune diseases, it may be the result of autoantibody producing against FⅧ, and some cases of AHA may act as the first manifestation of SLE. AHA should be suspected in patients who have spon-taneously hemorrhagic events with an isolated prolonged activated partial thromboplastin time (APTT), reduced FⅧ activity and a negative lupus anticoagulant (LA). When FⅧ inhibitor is found, it can be diagnosed. The management of AHA focuses on the following goals: (1)controlling and preventing blee-ding,(2)eradication of the inhibitor,(3)treatment of the underlying disease. Here, a case of AHA in a patient with lupus is reported. A 53-year-old man with a 4-year history of SLE developed arthralgia and ecchymotic skin lesions after arthrocentesis of knee joint. Ultrasound confirmed the presence of an intramuscular hematoma. Coagulation tests revealed that FⅧ activity reduced to 1% and a prolonged APTT (92.2 s), FⅧ inhibitors were found to be as high as 60.0 Bethesda Units. Initial treatments with me-thylprednisolone 200 mg/d were started but new hemorrhagic manifestation occurred and hisbiological indexes were not good. Then the patient was treated with intravenous pulse corticosteroids (methylprednisolone 500 mg/d),intravenous cyclophosphamide, and also plasma and prothrombin complex infusion. Sub-sequently, FⅧ activity returned within normal ranges, FⅧ inhibitors decreased and clinical improvement was significantly obtained. The patient’s condition kept stable till now.Hemorrhagic events due to produc-tion of antibodies directed against coagulation factors were rarely observed in SLE and attentions should be paid to the association between SLE and AHA.Bypass treatment was considered as the immediate antihemorrhagic treatment. Corticosteroid combined with immunosuppressor was recommended as the main therapy to eradicate the inhibitors. However we still lack the therapeutic guide-lines and standar-dized treatment in patients of AHA with SLE at present.

Key words: Systemic lupus erythematosus, Acquired hemophilia A, Immunosuppressor

CLC Number: 

  • R593.24

Figure 1

Multiple-site ecchymotic skin lesions and intramuscular hematomasA,ecchymotic skin lesions and intramuscular hematomas in knee-joints;B,ecchymotic skin lesions in the elbow joint."

[1] 郑东辉, 张白玉, 戴冽 , 等. 自身免疫性疾病合并获得性血友病A 4例临床分析并文献复习[J]. 中华风湿病学杂志, 2009,13(10):719-720.
doi: 10.3760/cma.j.issn.1007-7480.2009.10.019
[2] 冯云路, 郑文洁, 李剑 , 等. 结缔组织病相关获得性血友病甲4例报告并文献复习[J]. 北京医学, 2010,32(2):83-85.
doi: 10.3969/j.issn.1673-5552.2006.07.039
[3] O’Connor CR . Systematic reviewof thepresentation of coagulationfactor Ⅷ inhibitors in rheumatic diseases: a potential cause of life-threatening hemorrhage[J]. Semin Arthritis Rheum, 2015,44(6):695-709.
doi: 10.1016/j.semarthrit.2014.11.008 pmid: 25595725
[4] Delgado J, Jimenez-Yuste V, Hernandez-Navarro F , et al. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors[J]. Br J Haematol, 2003,121(1):21-35.
doi: 10.1046/j.1365-2141.2003.04162.x pmid: 12670328
[5] Chai-Adisaksopha C, Rattarittamrong E, Norasetthada L , et al. Younger age at presentation of acquired haemophilia A in Asian countries: a single-centre study and systematic review[J]. Haemophilia, 2014,20(3):e205-e210.
doi: 10.1111/hae.12383 pmid: 24847520
[6] Collins PW, Hirsch S, Baglin TP , et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation[J]. Blood, 2007,109(5):1870-1877.
doi: 10.1182/blood-2006-06-029850 pmid: 17047148
[7] Knoebl P, Marco P, Baudo F , et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)[J]. Thromb Haemost, 2012,10(4):622-631.
doi: 10.1111/j.1538-7836.2012.04654.x pmid: 22321904
[8] Khodamoradi Z, Nazarinia MA, Bazdar S . Acquired hemophilia as initial presentation in a patient with systemic lupus erythematosus[J]. CurrRheumatol Rev, 2017,13(3):236-238.
doi: 10.2174/1573397113666170519121952 pmid: 28523993
[9] 白松婷, 盛光耀 . 1-脱氨基-8-D-精氨酸血管加压素治疗血友病的研究进展[J]. 中华妇幼临床医学杂志, 2011,7(5):476-480.
doi: 10.3877/cma.j.issn.1673-5250.2011.05.020
[10] 中华医学会血液学分会血栓与止血学组, 中国血友病协作组. 获得性血友病A诊断与治疗中国专家共识[J]. 中华血液学杂志, 2014,35(6):575-576.
doi: 10.3760/cma.j.issn.0253-2727.2014.06.026
[11] Huth-Kühne A, Baudo F, Collins P , et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A[J]. Haematologica, 2009,94(4):566-575.
doi: 10.3324/haematol.2008.001743
[12] Kruse-Jarres R, Kempton CL, Baudo F , et al. Acquired hemophilia A: pdated review of evidence and treatment guidance[J]. Am J Hematol, 2017,92(7):695-705.
doi: 10.1002/ajh.24777 pmid: 28470674
[1] Zhihui WU, Mingzhi HU, Qiaoying ZHAO, Fengfeng LV, Jingying ZHANG, Wei ZHANG, Yongfu WANG, Xiaolin SUN, Hui WANG. Immunomodulatory mechanism of umbilical cord mesenchymal stem cells modified by miR-125b-5p in systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 860-867.
[2] Limin REN,Chuchu ZHAO,Yi ZHAO,Huiqiong ZHOU,Liyun ZHANG,Youlian WANG,Lingxun SHEN,Wenqiang FAN,Yang LI,Xiaomei LI,Jibo WANG,Yongjing CHENG,Jiajing PENG,Xiaozhen ZHAO,Miao SHAO,Ru Li. Low disease activity and remission status of systemic lupus erythematosus in a real-world study [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 273-278.
[3] Xiang-ge ZHAO,Jia-qing LIU,Hui-na HUANG,Zhi-min LU,Zi-ran BAI,Xia LI,Jing-jing QI. Interferon-α mediating the functional damage of CD56dimCD57+natural killer cells in peripheral blood of systemic lupus erythematosuss [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 975-981.
[4] Hai-hong YAO,Fan YANG,Su-mei TANG,Xia ZHANG,Jing HE,Yuan JIA. Clinical characteristics and diagnostic indicators of macrophage activation syndrome in patients with systemic lupus erythematosus and adult-onset Still's disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 966-974.
[5] Zhi-jun LUO,Jia-jia WU,You SONG,Chun-li MEI,Rong DU. Systemic lupus erythematosus associated macrophage activation syndrome with neuropsychiatric symptoms: A report of 2 cases [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1111-1117.
[6] Miao SHAO,Hui-fang GUO,Ling-yan LEI,Qing ZHAO,Yan-jie DING,Jin LIN,Rui WU,Feng YU,Yu-cui LI,Hua-li MIAO,Li-yun ZHANG,Yan DU,Rui-ying JIAO,Li-xia PANG,Li LONG,Zhan-guo LI,Ru LI. A multicenter study on the tolerance of intravenous low-dose cyclophosphamide in systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1112-1116.
[7] Min LI,Lin-qing HOU,Yue-bo JIN,Jing HE. Clinical and immunological characteristics of systemic lupus erythematosus with retinopathy [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1106-1111.
[8] Lin-qi ZHANG,Jing ZHAO,Hong-yan WANG,Zong-yi WANG,Ying-ni LI,Ji-yang TANG,Si-ying LI,Jin-feng QU,Ming-wei ZHAO. Relationship between anti-ENO1 antibody and systemic lupus erythematosus patients with retinopathy [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1099-1105.
[9] Jian-mei ZOU,Li-jun WU,Cai-nan LUO,Ya-mei SHI,Xue WU. Relationship of serum 25- hydroxy vitamin D and systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 938-941.
[10] XIA Fang-fang,LU Fu-ai,LV Hui-min,YANG Guo-an,LIU Yuan. Clinical characteristics and related factors of systemic lupus erythematosus with interstitial pneumonia [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 266-272.
[11] Yan GENG,Bo-rui LI,Zhuo-li ZHANG. Musculoskeletal ultrasound findings of symptomatic joints in patients with systemic lupus erythematosus [J]. Journal of Peking University(Health Sciences), 2020, 52(1): 163-168.
[12] Yu-hua WANG,Guo-hua ZHANG,Ling-ling ZHANG,Jun-li LUO,Lan GAO. Adrenal hemorrhage in a patient with systemic lupus erythematosus [J]. Journal of Peking University(Health Sciences), 2019, 51(6): 1178-1181.
[13] Ying-ni LI,Xiao-hong XIANG,Jing ZHAO,Yun LI,Feng SUN,Hong-yan WANG,Ru-lin JIA,Fan-lei HU. Significance of anti-carbamylated fibrinogen antibodies in systemic lupus erythematosus [J]. Journal of Peking University(Health Sciences), 2019, 51(6): 1019-1024.
[14] Xiao-hui ZHANG,Xue-rong DENG,Fan Li,Ying ZHU,Zhuo-li ZHANG. Posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a case report [J]. Journal of Peking University(Health Sciences), 2018, 50(6): 1102-1107.
[15] Shuang LIU,Yu-long GUO,Jing-yi YANG,Wei WANG,Jian XU. Efficacy of mesenchymal stem cells on systemic lupus erythematosus:a meta-analysis [J]. Journal of Peking University(Health Sciences), 2018, 50(6): 1014-1021.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!